USANA Health Sciences (USNA) Panoramica del titolo
USANA Health Sciences, Inc. sviluppa, produce e vende prodotti nutrizionali, per la cura della persona e della pelle a base scientifica nell'area Asia-Pacifico, nelle Americhe e in Europa. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 2/6 |
| Crescita futura | 3/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 6/6 |
| Dividendi | 0/6 |
Premi
Analisi del rischio
USNA Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di USANA Health Sciences, Inc.
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$22.11 |
| Massimo di 52 settimane | US$32.32 |
| Minimo di 52 settimane | US$16.60 |
| Beta | 0.73 |
| Variazione di 1 mese | 1.80% |
| Variazione a 3 mesi | 14.26% |
| Variazione di 1 anno | -23.39% |
| Variazione a 3 anni | -66.65% |
| Variazione a 5 anni | -77.13% |
| Variazione dall'IPO | 3,528.31% |
Notizie e aggiornamenti recenti
Seeking Alpha • Jun 19
USANA Health Sciences: How The Restructuring Plan Makes It A Strong Buy
Summary USANA Health Sciences is undergoing restructuring, causing temporary margin pressure but positioning for significant future profit expansion. Rise Wellness posted 740% revenue growth, but gross margin fell to 7.1% due to promotional discounts; margin recovery is expected as restocking begins at regular prices. Hiya's revenue dropped 13.3% amid higher CAC from Meta algorithm changes; in-house manufacturing should drive cost savings in H2. I assign USNA a Buy rating with a $30.8/share target, citing undervaluation (1.92x forward EV/EBITDA) and strong cash position. Read the full article on Seeking Alpha
Aggiornamento narrativa • Jun 17
USNA: Wellness Product Expansion And Buybacks Will Support Stock Upside
Analysts have maintained their $39.00 price target for USANA Health Sciences, citing largely unchanged assumptions for discount rate, revenue growth, profit margin, and future P/E in their updated models. What’s in the News for USANA Health Sciences USANA Health Sciences reiterated earnings guidance for fiscal 2026, with expected consolidated net sales of $925 million to $1.0b, net earnings of $20 million to $27 million, and diluted EPS of $1.11 to $1.45 per share.Aggiornamento narrativa • Jun 01
USNA: Skincare And Wellness Launches Will Support Future Upside Potential
Analysts have adjusted their price target for USANA Health Sciences to $39.00. Updated assumptions around discount rate, revenue growth, profit margin, and future P/E have shaped this new view on the stock.Recent updates
Seeking Alpha • Jun 19
USANA Health Sciences: How The Restructuring Plan Makes It A Strong Buy
Summary USANA Health Sciences is undergoing restructuring, causing temporary margin pressure but positioning for significant future profit expansion. Rise Wellness posted 740% revenue growth, but gross margin fell to 7.1% due to promotional discounts; margin recovery is expected as restocking begins at regular prices. Hiya's revenue dropped 13.3% amid higher CAC from Meta algorithm changes; in-house manufacturing should drive cost savings in H2. I assign USNA a Buy rating with a $30.8/share target, citing undervaluation (1.92x forward EV/EBITDA) and strong cash position. Read the full article on Seeking AlphaAggiornamento narrativa • Jun 17
USNA: Wellness Product Expansion And Buybacks Will Support Stock Upside
Analysts have maintained their $39.00 price target for USANA Health Sciences, citing largely unchanged assumptions for discount rate, revenue growth, profit margin, and future P/E in their updated models. What’s in the News for USANA Health Sciences USANA Health Sciences reiterated earnings guidance for fiscal 2026, with expected consolidated net sales of $925 million to $1.0b, net earnings of $20 million to $27 million, and diluted EPS of $1.11 to $1.45 per share.Aggiornamento narrativa • Jun 01
USNA: Skincare And Wellness Launches Will Support Future Upside Potential
Analysts have adjusted their price target for USANA Health Sciences to $39.00. Updated assumptions around discount rate, revenue growth, profit margin, and future P/E have shaped this new view on the stock.Articolo di analisi • May 08
Results: USANA Health Sciences, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
As you might know, USANA Health Sciences, Inc. ( NYSE:USNA ) just kicked off its latest first-quarter results with some...Aggiornamento narrativa • Apr 26
USNA: Costco Expansion Of New Wellness Beverage Will Support Upside
Analysts have maintained their $39.0 price target for USANA Health Sciences, noting that small changes in the discount rate, revenue growth, profit margin, and future P/E assumptions in their updated models largely offset one another. What's in the News USANA Malaysia hosted a large slow jogging event on April 11, 2026, tied to the launch of its Vitamin D product, attracting over 1,000 onsite and online participants and earning a Malaysia Book of Records title for simultaneous acupressure slow jogging (Key Developments).Aggiornamento narrativa • Apr 08
USNA: Costco Beverage Rollout And CEO Return Will Support Upside
The updated analyst price target for USANA Health Sciences now aligns with a fair value estimate of $39.00, as analysts fine tune their assumptions for discount rate, revenue, profit margin and future P/E to reflect current conditions. What's in the News Subsidiary Rise Wellness launched Protein Pop Plus, a clear, carbonated ready to drink protein beverage with 30 grams of protein per 12 ounce can, now available at all 607 Costco locations across the United States, expanding on the original Protein Pop line sold at Target stores (Key Developments).Aggiornamento narrativa • Mar 25
USNA: CEO Return And Costco Distribution Expansion Will Support Future Upside
Analysts have made only a minimal adjustment to their fair value estimate for USANA Health Sciences, keeping it effectively unchanged at about $39.00. Small tweaks to the discount rate, revenue growth, profit margin, and future P/E assumptions offset each other.Aggiornamento narrativa • Mar 09
USNA: CEO Return And New Product Rollout Will Support Future Upside
Analysts have maintained their price target for USANA Health Sciences at about $39.00. This reflects only minor adjustments to assumptions about the discount rate, revenue growth, profit margin, and future P/E ratio, rather than a change in their overall view of the stock.Aggiornamento narrativa • Feb 22
USNA: CEO Return And Share Repurchases Will Support Future Upside
Analysts have nudged their price target for USANA Health Sciences slightly higher to $39, citing updated assumptions for discount rate, revenue growth, profit margin, and future P/E, which together point to a more refined view of the company’s valuation profile. What's in the News USANA Health Sciences plans to complete its long running share repurchase program announced in December 2015, having repurchased 8,544,925 shares, or 39.11%, for a total of $678.7 million.Aggiornamento narrativa • Feb 08
USNA: CEO Transition To Kevin Guest Will Support Future Upside
Analysts have held their price target for USANA Health Sciences at about $39.00. This reflects updated assumptions for a slightly lower discount rate, revenue growth, profit margin, and future P/E that together point to a broadly unchanged valuation view.Aggiornamento narrativa • Jan 24
USNA: Leadership Return And Index Removals Will Support Future Upside
Analysts have maintained their price target for USANA Health Sciences at US$39.00. This reflects a view that modestly adjusted assumptions for discount rate, revenue growth, profit margin, and future P/E still support the same fair value estimate.Aggiornamento narrativa • Jan 07
USNA: Index Removals And Steady Outlook Will Support Future Upside Potential
Analysts now hold their price target for USANA Health Sciences steady at about US$39, reflecting only minor tweaks to the discount rate, revenue growth, profit margin and forward P/E assumptions rather than a change in their overall view of the stock. What's in the News USANA Health Sciences, Inc.Aggiornamento narrativa • Dec 23
USNA: Index Removals Will Create Future Opportunity For Undervalued Upside Potential
Analysts have modestly raised their price target on USANA Health Sciences to 39.00 dollars from 39.00 dollars, reflecting slightly lower discount rate assumptions, materially higher projected revenue growth, a modestly lower profit margin outlook, and a marginally richer expected future price to earnings multiple. What's in the News Removed as a constituent from the S&P SmallCap 600 index, reducing passive index fund ownership and visibility among small cap investors (Index change notice).Aggiornamento narrativa • Dec 09
USNA: Active Acquisition Pursuits Will Drive Future Business Diversification Ahead
Analysts have modestly raised their price target on USANA Health Sciences to approximately $39.00, citing slightly higher long term growth assumptions and a marginal uptick in expected valuation multiples. What's in the News USANA Health Sciences was removed as a constituent from the S&P 600, S&P 1000, and S&P Composite 1500 indexes, as well as the S&P 600 Consumer Staples sector index, potentially reducing passive index fund ownership of the stock (Index Constituent Drops).Aggiornamento narrativa • Nov 25
USNA: Active M&A Efforts Will Drive Positive Business Diversification Ahead
Analysts have reiterated their price target for USANA Health Sciences at $39.00, citing consistent assumptions in revenue growth, profit margin, and valuation multiples. These factors support a stable outlook.Aggiornamento narrativa • Nov 08
USNA: Future Diversification Plans Will Drive Renewed Investor Optimism
Analysts have maintained their price target for USANA Health Sciences steady at $39.00. They cited consistent growth and profitability estimates as justification for holding the previous valuation.Aggiornamento narrativa • Oct 24
Share Repurchases And Product Expansion Will Drive Profitability And Brand Recognition
Analysts have revised their price target for USANA Health Sciences to $39.00. This reflects a recalibrated outlook based on modest revenue growth and improved profit margin expectations.Articolo di analisi • Oct 16
USANA Health Sciences, Inc. (NYSE:USNA) Looks Inexpensive After Falling 31% But Perhaps Not Attractive Enough
USANA Health Sciences, Inc. ( NYSE:USNA ) shareholders that were waiting for something to happen have been dealt a blow...Articolo di analisi • Oct 11
Returns On Capital At USANA Health Sciences (NYSE:USNA) Paint A Concerning Picture
There are a few key trends to look for if we want to identify the next multi-bagger. Firstly, we'd want to identify a...Aggiornamento narrativa • Oct 10
Modernized Sales Model And International Expansion Will Deliver Success
Analysts have significantly lowered their price target for USANA Health Sciences from $61 to $39. They cite reduced expectations for revenue growth and profit margins as key factors in the revised outlook.Articolo di analisi • Jul 18
USANA Health Sciences, Inc. (NYSE:USNA) Looks Inexpensive But Perhaps Not Attractive Enough
USANA Health Sciences, Inc.'s ( NYSE:USNA ) price-to-earnings (or "P/E") ratio of 16.3x might make it look like a buy...Articolo di analisi • May 12
Shareholders May Be Wary Of Increasing USANA Health Sciences, Inc.'s (NYSE:USNA) CEO Compensation Package
Key Insights USANA Health Sciences to hold its Annual General Meeting on 19th of May Total pay for CEO Jim Brown...Articolo di analisi • Apr 08
The Market Doesn't Like What It Sees From USANA Health Sciences, Inc.'s (NYSE:USNA) Earnings Yet As Shares Tumble 25%
The USANA Health Sciences, Inc. ( NYSE:USNA ) share price has fared very poorly over the last month, falling by a...Articolo di analisi • Apr 04
There Are Reasons To Feel Uneasy About USANA Health Sciences' (NYSE:USNA) Returns On Capital
To find a multi-bagger stock, what are the underlying trends we should look for in a business? One common approach is...Articolo di analisi • Dec 09
Should You Think About Buying USANA Health Sciences, Inc. (NYSE:USNA) Now?
USANA Health Sciences, Inc. ( NYSE:USNA ), might not be a large cap stock, but it received a lot of attention from a...Articolo di analisi • Sep 26
USANA Health Sciences (NYSE:USNA) Could Be Struggling To Allocate Capital
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
Nuova narrativa • Sep 24
India Expansion And Decisive Acquisitions Promise Growth Amid Analyst Concerns Over Shrinking Margins
Expansion into India and strategic acquisitions offer significant growth opportunities for USANA, potentially boosting revenue and diversifying its market presence.Articolo di analisi • Sep 08
Is There Now An Opportunity In USANA Health Sciences, Inc. (NYSE:USNA)?
While USANA Health Sciences, Inc. ( NYSE:USNA ) might not have the largest market cap around , it saw significant share...Articolo di analisi • Jul 26
USANA Health Sciences, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
As you might know, USANA Health Sciences, Inc. ( NYSE:USNA ) last week released its latest second-quarter, and things...Rendimenti per gli azionisti
| USNA | US Personal Products | US Mercato | |
|---|---|---|---|
| 7D | 3.7% | 0.03% | 0.9% |
| 1Y | -23.4% | -17.1% | 17.5% |
Ritorno vs Industria: USNA ha avuto una performance inferiore rispetto al US Personal Products che ha registrato un rendimento -17.1 % nell'ultimo anno.
Rendimento vs Mercato: USNA ha avuto una performance inferiore al mercato US che ha registrato un rendimento 17.5 % nell'ultimo anno.
Volatilità dei prezzi
| USNA volatility | |
|---|---|
| USNA Average Weekly Movement | 6.4% |
| Personal Products Industry Average Movement | 8.4% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
Prezzo delle azioni stabile: USNA non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale ( 6% ) di USNA è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1992 | 1,570 | Kevin Guest | www.usana.com |
USANA Health Sciences, Inc. sviluppa, produce e vende prodotti nutrizionali, per la cura della persona e della pelle a base scientifica nell'area Asia-Pacifico, nelle Americhe e in Europa. Opera in due segmenti, Core Nutritional e Hiya Direct-To-Consumer. L'azienda offre ottimizzatori nutrizionali USANA, tra cui integratori per la salute cardiovascolare, scheletrica/strutturale e digestiva; Essentials/CellSentials, come integratori di vitamine e minerali per gruppi di età a partire dai bambini di 13 mesi; e prodotti alimentari che includono frullati sostitutivi del pasto, barrette e altri prodotti correlati per la gestione del peso sano, la salute digestiva, l'energia e l'idratazione.
USANA Health Sciences, Inc. Riepilogo dei fondamenti
| USNA statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$409.32m |
| Utili (TTM) | US$8.87m |
| Ricavi(TTM) | US$925.94m |
46.0x
Rapporto P/E0.4x
Rapporto P/SUSNA è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| USNA Conto economico (TTM) | |
|---|---|
| Ricavi | US$925.94m |
| Costo del fatturato | US$207.84m |
| Profitto lordo | US$718.09m |
| Altre spese | US$709.22m |
| Utili | US$8.87m |
Ultimi utili riportati
Apr 04, 2026
Prossima data di guadagno
Aug 04, 2026
| Utile per azione (EPS) | 0.48 |
| Margine lordo | 77.55% |
| Margine di profitto netto | 0.96% |
| Rapporto debito/patrimonio netto | 2.4% |
Come si è comportato USNA nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/07/31 13:47 |
| Prezzo dell'azione a fine giornata | 2026/07/31 00:00 |
| Utili | 2026/04/04 |
| Utili annuali | 2026/01/03 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
USANA Health Sciences, Inc. è coperta da 7 analisti. 1 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| John San Marco | Brean Capital Historical (Janney Montgomery) |
| Scott Van Winkle | Canaccord Genuity |
| Stephanie Schiller Wissink | Jefferies LLC |